| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 1 | +1.53 M | 72.2% | $38.00 | +$58 M |
| Sells | 10 | -588 K | 27.8% | $26.68 | -$15.7 M |
| Net | -9 | +939 K | 44.4% | +$42.3 M |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Roivant Sciences Ltd. | Director, 10%+ Owner | $3.03 B | +$58 M | +1.95% | Oct 2, 2023 |
| Peter Salzmann | Chief Executive Officer, Director | $29 M | -$8.76 M | -23.2% | Jul 9, 2024 |
| Frank Torti | Director | $23 M | Apr 2, 2024 | ||
| Julia G. Butchko | Chief Development Officer | $12.5 M | -$1.01 M | -7.48% | Jul 9, 2024 |
| William L. Macias | Chief Medical Officer | $11.1 M | -$822 K | -6.89% | May 22, 2024 |
| Mark S. Levine | Chief Legal Officer | $10.1 M | -$1.27 M | -11.2% | May 22, 2024 |
| Eva Renee Barnett | Chief Financial Officer | $9.84 M | -$1.64 M | -14.3% | Jul 9, 2024 |
| Douglas J. Hughes | Director | $4.52 M | Apr 2, 2024 | ||
| George V. Migausky | Director | $4.38 M | -$505 K | -10.3% | Apr 2, 2024 |
| Jay S. Stout | Chief Technology Officer | $4.27 M | -$209 K | -4.67% | Apr 24, 2024 |
| Atul Pande | Director | $4.14 M | -$491 K | -10.6% | Apr 2, 2024 |
| Michael Geffner | Chief Medical Officer | $4.09 M | -$477 K | -10.4% | Apr 24, 2024 |
| Andrew J. Fromkin | Director | $3.61 M | -$491 K | -12% | Apr 2, 2024 |
| Insider | Class | Transaction | % | Value $ | Price $ | Shares | Shares Owned | Date | Ownership |
|---|